A Phase 1, Open-Label, Dose Escalation and Dose Expansion, Multicenter Clinical Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Lomonitinib (ZE46-0134) in Adults with FLT3-Mutated Relapsed or Refractory Acute Myeloid Leukemia Meeting Abstract
| Authors: | Lin, T. L.; Koenig, K. L.; Swords, R. T.; Stein, E. M.; Baer, M. R.; Stock, W.; Madanat, Y. F.; Olin, R.; Blum, W.; Schiller, G. J.; Zeidner, J. F.; Curran, E. K.; Martycz, M.; Rosenberg, L.; Marcus, S. G.; Chen, T. M. Y.; Stefanos, M.; Burd, A.; Yocum, A. O.; Levine, R. L.; Druker, B. J.; Borate, U.; Byrd, J. C.; Mims, A. |
| Abstract Title: | A Phase 1, Open-Label, Dose Escalation and Dose Expansion, Multicenter Clinical Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Lomonitinib (ZE46-0134) in Adults with FLT3-Mutated Relapsed or Refractory Acute Myeloid Leukemia |
| Meeting Title: | Blood |
| Journal Title: | Blood |
| Volume: | 144 |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2024-11-01 |
| Language: | English |
| ACCESSION: | WOS:001415696500049 |
| DOI: | 10.1182/blood-2024-208822 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- 66th Annual Meeting of the American-Society-of-Hematology (ASH) -- DEC 06-09, 2025 -- 1 -- Orlando, FL -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work